Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Discovery of substituted \(N\)-(2-oxoindolin-3-ylidene)benzohydrazides as new apoptosis inducers using a cell- and caspase-based HTS assay

Nilantha Sirisoma, Azra Pervin, John Drewe, Ben Tseng, Sui Xiong Cai * 
EpiCept Corporation, 6650 Nancy Ridge Drive, San Diego, CA 92121, USA

**A R T I C L E   I N F O**

Article history:
Received 4 March 2009
Revised 23 March 2009
Accepted 25 March 2009
Available online 28 March 2009

Keywords:
Apoptosis inducer
Anticancer agent
HTS
SAR
Tubulin inhibitor

**A B S T R A C T**

We report the discovery of a series of substituted \(N\)-(2-oxoindolin-3-ylidene)benzohydrazides as inducers of apoptosis using our proprietary cell- and caspase-based ASAP HTS assay. Through SAR studies, \(N\)-(4-bromo-5-methyl-2-oxoindolin-3-ylidene)-3,4,5-trimethoxybenzohydrazide (3g) was identified as a potent apoptosis inducer with an EC\(_{50}\) value of 0.24 \(\mu\)M in human colorectal carcinoma HCT116 cells, more than a 40-fold increase in potency from the initial screening hit \(N\)-(5-bromo-2-oxoindolin-3-ylidene)-3,4,5-trimethoxybenzohydrazide (2a). Compound 3g also was found to be highly active in a growth inhibition assay with a GI\(_{50}\) value of 0.056 \(\mu\)M in HCT116 cells. A group of potentially more aqueous soluble analogs were prepared and found to be highly active. Among them, compound 4e incorporating a methyl piperazine moiety was found to have EC\(_{50}\) values of 0.17, 0.088 and 0.14 \(\mu\)M in human colorectal carcinoma cells HCT116, hepatocellular carcinoma cancer SNU398 cells and human colon cancer RKO cells, respectively. Compounds 3g and 4e were found to function as inhibitors of tubulin polymerization.

© 2009 Elsevier Ltd. All rights reserved.

Apoptosis, or program cell death, plays a crucial role in normal cell development and tissue homeostasis. Apoptosis is used by organisms to control their cell numbers and to eliminate unneeded or damaged cells. Inappropriate apoptosis induction is known to result in excessive cell death, and could cause degenerative diseases. Inadequate apoptosis, however, could lead to over proliferation of cells and cancer. In addition, it is known that the anti-tumor efficacy of many chemotherapeutical agents is correlated to their apoptosis inducing ability. Identification of compounds that promote or induce apoptosis in cancer cells, therefore, is an attractive approach for anticancer research.

We have been interested in the discovery and development of apoptosis inducers as potential anticancer agents. Applying our novel caspase-3 substrates, we have developed a caspase- and cell-based, high throughput screening technology, termed Apoptosis Screening and AntiCancer Platform (ASAP), for the identification of apoptosis inducers. We have reported the discovery of several novel series of apoptosis inducers, including 4-aryl-4H-chromenes (1a),10 gambogenic acid (1b),11 3-aryl-5-aryl-1,2,4-oxadiazoles (1c),12 N-phenyl-1H-pyrazolo[3,4-b]quinolin-4-amines (1d),13 4-anilinoquinazolines (1e),14,15 and 4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1H)-quinolinones (1f)16 (Chart 1). Herein we report the discovery of substituted \(N\)-(2-oxoindolin-3-ylidene)-benzohydrazide (2a), an isatin derivative, as an apoptosis inducer using our HTS assay. SAR study of 2a led to the discovery of \(N\)-(4-bromo-5-methyl-2-oxoindolin-3-ylidene)-3,4,5-trimethoxybenzohydrazide (3g) and analogs as potent apoptosis inducers.

Many isatins and isatin derivatives have been synthesized and reported to have a variety of biological activities, including as SARS coronavirus 3C-like protease inhibitors, caspase-3 inhibitors, and as inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2. More recently, N-alkyl isatin acylhydrazine derivatives such as 7a (Chart 2) have been reported to be potent and selective cannabinoid receptor 2 inverse agonists for the potential treatment of neuropathic pain. In addition, N-substituted isatins such as 7b have been reported to be cytotoxic with a mode of action that includes inhibition of tubulin polymerization, induction of G2/M cell cycle arrest and activation of caspase-3 and -7.

Substituted \(N\)-(5-bromo-2-oxoindolin-3-ylidene)-benzohydrazides 2a–2f were obtained from ChemDiv and Asinex, and their structures were confirmed by \(^1\)H NMR and MS. Substituted \(N\)-(2-oxoindolin-3-ylidene)-3,4,5-trimethoxybenzohydrazides 3a–3m were prepared from condensation of the corresponding substituted isatin (5) with substituted 3,4,5-trimethoxybenzohydrazide (6) according to reported procedures. \(^{20,22}\) The N-substituted analogs 4a–4h were prepared from condensation of 2a, 3a, 3g and 3h with formaldehyde and an amine following literature procedures (Scheme 1).

The apoptosis inducing activity of substituted \(N\)-(2-oxoindolin-3-ylidene)-benzohydrazides was measured using our cell- and cas-
pase-based HTS assay\(^7\) in human colorectal carcinoma cells HCT116, hepatocellular carcinoma cancer SNU398 cells and human colon cancer RKO cells, and the results are summarized in Tables 1–3. Compound 2a was found to have EC\(_{50}\) values of 4–10 \(\mu\)M in the three cell lines tested. By maintaining the 5-bromo group in the isatin, we explored replacement of the 3,4,5-trimethoxy groups in the benzoyl group of 2a by other groups. Table 1 showed that, except for compound 2b, all these compounds (2c–2f) were inactive up to 20 \(\mu\)M in all the three cell lines, indicating that the 3,4,5-trimethoxy group is preferred.

By maintaining the 3,4,5-trimethoxybenzoyl group, we then explored substitutions in the 4- to 7-positions of isatin ring (Table 2). The 5-methoxy (3a) and 5-iodo (3b) analogs were similar or slightly more active than 2a. The 5-trifluoromethoxy (3c), 5-amino (3d) and 5-acetylamino (3e) analogs were less active or inactive in

![Chart 2.](image)

**Table 1**
Activity of substituted \(N\)-\((5\text{-bromo-2-oxoindolin-3-ylidene})\)-benzohydrazides in the caspase activation assay

| Compound # | R\(^1\) | R\(^2\) | R\(^3\) | R\(^4\) | EC\(_{50}\) \((\mu\)M\) |
|------------|---------|---------|---------|---------|-------------------|
| 2a         | H       | OMe     | OMe     | OMe     | HCT116: \(10.7 \pm 0.5\) SNU398: \(8.9 \pm 0.2\) RKO: \(4.4 \pm 0.5\) |
| 2b         | H       | H       | O\(\text{CH}_2\text{O}\) | H       | >20 >20 >20 |
| 2c         | OMe     | H       | H       | H       | >20 >20 >20 |
| 2d         | H       | H       | H       | Br      | >20 >20 >20 |
| 2e         | H       | H       | H       | NO\(_2\) | >20 >20 >20 |
| 2f         | H       | H       | H       | H       | >20 >20 >20 |

\(^a\) Cells were treated with the test compounds for 48 h, and data are the mean of three or more experiments and are reported as mean ± standard error of the mean (SEM).
the three cell lines. These data suggested that strong electron withdrawing, or hydrophilic, or large groups are not favored at the 5-position. The 4-chloro analog 3f was >2-fold more potent than 2a in all the three cell lines, indicating that a small group at the 4-position might increase potency. Combination of substitutions at both the 4- and 5-positions led to the 4-bromo-5-methyl analog 3g that was highly potent with an EC50 value of 0.24 μM in HCT116 cells, >40-fold more potent than 2a. The 4,5-dichloro analog 3h also was highly active. Interestingly, 5-methyl-4-phenyl analog 3i was inactive up to 20 μM, indicating that a large group is not tolerated at 4-position. 5,6-Di-substituted analogs (3j and 3k) and 5,7-di-substituted analogs (3l and 3m) were found to have low activity or inactive, suggesting that substitutions at the 6- and 7-positions may not be preferred.

To explore the SAR further and to improve the aqueous solubility, we introduced an N-morpholinomethyl group into the nitrogen of the isatin of compounds 2a, 3a, 3g and 3h. Table 3 showed that compounds 4a–4d had activities similar to the corresponding non-N-substituted analogs. Several compounds with various aminomethyl groups were prepared from 3g and found to be highly active. Compounds 4e and 4f were the most potent ones, both with EC50 values of 0.17 μM. These data indicated that substitution at the nitrogen of isatin is tolerated and it could be used to introduce aqueous solubility enhancing groups.

Overall, the apoptosis inducing activities of these compounds in human colon cancer HCT116 cells were similar to that observed in hepatocellular carcinoma cancer SNU398 cells and human colon cancer RKO cells (Tables 1–3). Compound 3g, 4e and 4f, three of

| Compound # | R1 | R2 | R3 | EC50 (μM)a |
|------------|----|----|----|-------------|
| 3a         | H  | OMe| H  | 6.6 ± 0.8   |
| 3b         | H  | I  | H  | 10.5 ± 0.2  |
| 3c         | H  | OCF3| H | >20         |
| 3d         | H  | NH2| H  | >20         |
| 3e         | H  | AcNH| H | >20         |
| 3f         | Cl | H  | H  | 3.8 ± 0.3   |
| 3g         | Br | Me | H  | 0.24 ± 0.03 |
| 3h         | Cl | Cl | H  | 0.64 ± 0.02 |
| 3i         | Ph | Me | H  | >20         |
| 3j         | H  | Me | Br | 8.4 ± 1.1   |
| 3k         | H  | OMe| Br | >20         |
| 3l         | H  | Cl | Cl | >20         |
| 3m         | H  | Me | Br | 10.6 ± 0.1  |

* Cells were treated with the test compounds for 48 h, and data are the mean of three or more experiments and are reported as mean ± standard error of the mean (SEM).

| Compound # | R1 | R2 | R3 | EC50 (μM)a |
|------------|----|----|----|-------------|
| 4a         | H  | Br | N  | >20         |
| 4b         | H  | OMe| N  | >20         |
| 4c         | Cl | Cl | N  | 0.49 ± 0.09 |
| 4d         | Br | Me | N  | 0.31 ± 0.04 |
| 4e         | Br | Me | N  | 0.17 ± 0.02 |
| 4f         | Br | Me | N  | 0.17 ± 0.03 |
| 4g         | Br | Me | N  | 0.25 ± 0.01 |
| 4h         | Br | Me | N  | 0.25 ± 0.02 |

* Cells were treated with the test compounds for 48 h, and data are the mean of three or more experiments and are reported as mean ± standard error of the mean (SEM).
the most active compounds in HCT116 cells, also were the most active ones in SNU398 and RKO cells, suggesting that these compounds most probably will be broadly active against many cancer cell lines.

Representative compounds were assayed in a traditional growth inhibition (GI50) assay to confirm that the active compounds in the caspase induction assay also inhibit tumor cell growth. The growth inhibition assays in T47D, HCT116 and SNU398 cells were run in a 96-well microtiter plate as described previously7 and the data are summarized in Table 4. Compound 3g had GI50 values of 0.056, 0.022 and 0.019 μM in HCT116, SNU398 and RKO cells, respectively, which are >100-fold more active than the original hit compound SNU398 and RKO cells, respectively, which are >100-fold more active than the screening hit 2a. The mode of action for the potent compounds 3g and 4e was found to be inhibition of tubulin polymerization.

Table 4
Growth inhibition activity of substituted N-(2-oxoindolin-3-ylidine)-3,4,5-trimethoxybenzohydrazides

| Compound # | HCT116 | SNU398 | RKO |
|------------|--------|--------|-----|
| 2a         | 7.1 ± 1.1 | 2.7 ± 0.1 | 2.7 ± 1.2 |
| 3g         | 0.056 ± 0.015 | 0.022 ± 0.008 | 0.019 ± 0.003 |
| 3h         | 0.32 ± 0.14 | 0.14 ± 0.04 | 0.054 ± 0.012 |
| 4d         | 0.062 ± 0.008 | 0.026 ± 0.011 | 0.019 ± 0.003 |
| 4e         | 0.051 ± 0.018 | 0.023 ± 0.008 | 0.018 ± 0.004 |
| 4f         | 0.088 ± 0.043 | 0.024 ± 0.006 | 0.036 ± 0.012 |
| 4h         | 0.086 ± 0.008 | 0.029 ± 0.014 | 0.043 ± 0.016 |

* Cells were treated with the test compounds for 48 h, and data are the mean of three experiments and are reported as mean ± standard error of the mean (SEM).

utilizing our ASAP assay. Through SAR studies, potent compound 3g and significantly more aqueous soluble compound 4e were identified with EC50 values in HCT116 cells >40-fold more potent than the screening hit 2a. The mode of action for the potent compounds 3g and 4e was found to be inhibition of tubulin polymerization.

References and notes

1. Henson, P. M.; Bratton, D. L.; Fadok, V. A. Curr. Biol. 2001, 11, R795.
2. Reed, J. C.; Tomasselli, K. J. Curr. Opin. Biotechnol. 2000, 11, 586.
3. Robertson, G. S.; Crocker, S. J.; Nicholson, D. W.; Schulz, J. B. Brain Pathol. 2000, 10, 283.
4. Reed, J. C. Nat. Rev. Drug Disc. 2002, 1, 111.
5. Vial, J. P.; Belloch, F.; Dumain, P.; Bernard, S.; Lacombe, F.; Boisseau, M. R.; Reiffers, J.; Bernard, P. Leucocyte Res. 1997, 23, 1, 163.
6. Li, Q.-X.; Yu, D. H.; Liu, G.; Ke, N.; McKelvy, J.; Wong-Staal, F. Cell Death Differ. 2008, 15, 1197.
7. Cai, S. X.; Nguyen, B.; Jia, S.; Herich, J.; Guastella, J.; Reddy, S.; Tseng, B.; Drewe, J.; Kasibhatla, S. J. Med. Chem. 2003, 46, 2474.
8. Cai, S. X.; Zhang, H.-Z.; Guastella, J.; Drewe, J.; Yang, W.; Weber, E. Bioorg. Med. Chem. Lett. 2001, 11, 39.
9. Cai, S. X.; Drewe, J.; Kasibhatla, S. Curr. Med. Chem. 2006, 13, 2627.
10. Kemnitzer, W.; Kasibhatla, S.; Jiang, S.; Zhang, H.; Wang, Y.; Zhao, J.; Jia, S.; Herich, J.; Labreque, D.; Storer, R.; Meeroivitch, K.; Boufard, D.; Rej, R.; Denis, R.; Blais, C.; Lamothe, S.; Attardo, C.; Gourdeau, H.; Tseng, B.; Drewe, J.; Cai, S. X. J. Med. Chem. 2004, 47, 6299.
11. Zhang, H.-Z.; Kasibhatla, S.; Wang, Y.; Herich, J.; Guastella, J.; Tseng, B.; Drewe, J.; Cai, S. X. Bioorg. Med. Chem. 2004, 12, 309.
12. Zhang, H.-Z.; Kasibhatla, S.; Kuennmerle, J.; Kemnitzer, W.; Ohlis-Mason, K.; Qui, L.; Crogan-Grundy, C.; Tseng, B.; Drewe, J.; Cai, S. X. J. Med. Chem. 2005, 48, 5215.
13. Zhang, H.-Z.; Claassen, G.; Crogan-Grundy, C.; Tseng, B.; Drewe, J.; Cai, S. X. Bioorg. Med. Chem. 2008, 16, 222.
14. Sirisoma, N.; Kasibhatla, S.; Pervin, A.; Zhang, H.; Jiang, S.; Willardsen, J. A.; Anderson, M.; Baichwal, V.; Mathur, G. G.; Jessing, K.; Hussain, R.; Hoang, K.; Pleiman, C. M.; Tseng, B.; Drewe, J.; Cai, S. X. J. Med. Chem. 2008, 51, 4771.
15. Kasibhatla, S.; Baichwal, V.; Cai, S. X.; Roth, B.; Skvortsova, I.; Skvortsov, S.; Lukas, P.; English, N. M.; Sirisoma, N.; Drewe, J.; Pervin, A.; Tseng, B.; Carlson, R. O.; Pleiman, C. M. Cancer Res. 2007, 67, 5865.
16. Claassen, G.; Brin, E.; Crogan-Grundy, C.; Vaillancourt, M. T.; Zhang, H.-Z.; Cai, S. X.; Drewe, J.; Tseng, B.; Kasibhatla, S. Cancer Lett. 2009, 274, 243.
17. Zhou, L.; Liu, Y.; Zhang, W.; Wei, P.; Huang, C.; Pei, J.; Yuan, Y.; Lai, J. L. Med. Chem. 2006, 49, 3440.
18. Chu, W.; Zhang, J.; Zheng, C.; Rothfuss, J.; Tu, Z.; Chu, Y.; Reichert, D. E.; Welch, M. J.; Mach, R. H. J. Med. Chem. 2005, 48, 7637.
19. Lawrence H. R.; Pireddu, R.; Chen, L.; Luo, Y.; Sung, S.-S.; Szymanski, A. M.; Yip, M. L. R.; Guida, W. C.; Sebti, S. M.; Wu, J.; Lawrence, N. J. J. Med. Chem. 2008, 51, 4948.
20. Diaz, P.; Phatak, S. S.; Xu, J.; Astruc-Diaz, F.; Cavastroni, C. N.; Naguib, M. J. Med. Chem. 2009, 52, 433.
21. Vain, K. L.; Locke, J. M.; Ranson, M.; Pyne, S. G.; Bremmer, J. B. J. Med. Chem. 2007, 50, 5109.
22. Diaz, P.; Xu, J.; Astruc-Diaz, F.; Pan, H.-M.; Brown, D. L.; Naguib, M. J. Med. Chem. 2008, 51, 4932.
23. Lingasa, N.; Narender, R.; Dattatray, A. Indian J. Chem. B 1998, 37, 1254.
24. Pirrong, M. C.; Pansare, S. V.; Sarma, K. D.; Keith, K. A.; Kern, E. R. J. Med. Chem. 2005, 48, 3045.
25. Barron, D. M.; Chatterjee, S. K.; Ravindra, R.; Roof, R.; Baloglu, E.; Kingston, D. G. I.; Bane, S. Anal. Biochem. 2003, 315, 49.